Skip to content
2000
Volume 11, Issue 8
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

Pyrazolic compounds represent a large source of anticancer compounds, based on the choice of the scaffold structure, the nature of the substituents and the sites of coordination. Here, we discuss our recent progresses in identifying new active molecules from a synthetic library of 14 nitrogen compounds. All these compounds exert antiproliferative activity against breast and colorectal cancer cell lines with varying IC50 values (the half-maximal inhibitory concentration, which is a measure of the effectiveness of a compound in inhibiting biological or biochemical function). We found a onelog order difference in activity among the different tested compounds. The most active compound 7 showed an IC50 values equal to 8.5μg/ml in both MDA-MB 231(breast cancer) and LOVO (colorectal cancer) cell lines.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/1570180811666140512220842
2014-10-01
2025-06-22
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/1570180811666140512220842
Loading

  • Article Type:
    Research Article
Keyword(s): Anti-cancer; LOVO; MDA-MB231; MTT assay; Normoxie conditions and drug design; Pyrazole
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test